Compass Therapeutics (CMPX) Cash from Financing Activities (2018 - 2026)
Compass Therapeutics recorded quarterly Cash from Financing Activities of $3.4 million in Q1 2026, up 216.56% quarter-over-quarter from $1.1 million in Q4 2025, and up 512.88% year-over-year from $549044.0 in Q1 2025.
Compass Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 512.88% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $133.8 million (up 14802.09% YoY), while the FY2025 annual figure was $129.6 million, up 647.54% from the prior year.
- Cash from Financing Activities came in at $3.4 million for Q1 2026 at Compass Therapeutics, up from $1.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $129.4 million in Q3 2025 to a low of -$815000.0 in Q1 2025.
- A 5-year average of $16.4 million and a median of $31000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities sank 109.52% in 2024 and surged 6468150.0% in 2025, its largest moves.
- Compass Therapeutics' Cash from Financing Activities stood at $75.8 million in 2022, then plunged by 100.21% to -$158000.0 in 2023, then soared by 40.51% to -$94000.0 in 2024, then jumped by 1230.85% to $1.1 million in 2025, then soared by 216.56% to $3.4 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.4 million, $1.1 million, and $129.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | 3.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.37 Mn |
| Mar 31, 2026 | 3.37 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 129.36 Mn |
| Sep 30, 2025 | 129.36 Mn |
| Mar 31, 2025 | -815,000.00 |
| Mar 31, 2025 | -815,000.00 |
| Dec 31, 2024 | -94,000.00 |
| Dec 31, 2024 | -94,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | 17.43 Mn |
| Mar 31, 2024 | 17.43 Mn |
| Dec 31, 2023 | -158,000.00 |
| Dec 31, 2023 | -158,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 3.03 Mn |
| Jun 30, 2023 | 3.03 Mn |
| Mar 31, 2023 | 41,000.00 |
| Mar 31, 2023 | 41,000.00 |
| Dec 31, 2022 | 75.75 Mn |
| Dec 31, 2022 | 75.75 Mn |
| Sep 30, 2022 | 5,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Dec 31, 2021 | 124.24 Mn |
| Dec 31, 2021 | 124.24 Mn |
| Sep 30, 2021 | -1.88 Mn |
| Sep 30, 2021 | -1.88 Mn |
| Jun 20, 2021 | -1.88 Mn |
| Jun 20, 2021 | -1.88 Mn |
| Mar 31, 2021 | -1.88 Mn |
| Mar 31, 2021 | -1.88 Mn |
| Sep 30, 2020 | 50.41 Mn |
| Sep 30, 2020 | 50.41 Mn |
| Jun 30, 2020 | 53.09 Mn |
| Jun 30, 2020 | 53.09 Mn |
| Dec 31, 2019 | 20,985.00 |
| Dec 31, 2019 | 20,985.00 |
| Dec 31, 2018 | 12,500.00 |
| Dec 31, 2018 | 12,500.00 |
| Jun 30, 2018 | 15,125.00 |
| Jun 30, 2018 | 15,125.00 |